Get the Stockscreener App
15.68
1.26%
-0.20
Sarepta Therapeutics Inc stock is traded at $15.68, with a volume of 2.14M.
It is down -1.26% in the last 24 hours and down -6.08% over the past month.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
See More
Previous Close:
$15.88
Open:
$15.88
24h Volume:
2.14M
Relative Volume:
0.65
Market Cap:
$1.66B
Revenue:
$2.18B
Net Income/Loss:
$-64.32M
P/E Ratio:
-16.26
EPS:
-0.9641
Net Cash Flow:
$91.18M
1W Performance:
-8.94%
1M Performance:
-6.08%
6M Performance:
-25.79%
1Y Performance:
+21.74%
1-Day Range:
$15.49
$16.03
1-Week Range:
$15.43
$17.70
52-Week Range:
$11.12
$25.32
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
15.68 | 1.66B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Dec-09-25 | Initiated | Wedbush | Outperform |
| Nov-05-25 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Sarepta Therapeutics, Inc. Revenue Breakdown – NASDAQ:SRPT - TradingView
Sarepta Therapeutics stock steadies as investors weigh Elevidys expansion and revenue trajectory - AD HOC NEWS
SRPT: Sarepta Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results - BioSpace
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - Yahoo Finance
Press Release: Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results - Moomoo
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space - Stocktwits
Sarepta Therapeutics Stock Short Interest Rises to 32.62% - Quiver Quantitative
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 28.77% Potential Upside for Investors - DirectorsTalk Interviews
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress? - Sahm
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - TradingView
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next - Stocktwits
Trading Systems Reacting to (SRPT) Volatility - Stock Traders Daily
SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT) - Supply Chain Digital
Is Sarepta Therapeutics (SRPT) Undervalued Following FDA Progress On AMONDYS 45 And VYONDYS 53? - Sahm
Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued? - Yahoo Finance
The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies - Yahoo Finance
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape - DirectorsTalk Interviews
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout - AOL.com
Barclays Upgrades Sarepta Therapeutics (SRPT) - MSN
Sarepta Therapeutics (SRPT) Proxy filing Summary - Quartr
SRPT Maintained by Piper Sandler -- Price Target Lowered to $20. - GuruFocus
SRPT Upgraded by Wolfe Research -- Rating Changed to Outperform - GuruFocus
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53® - Sarepta Therapeutics
Wolfe Research upgrades Sarepta Therapeutics stock rating on pipeline outlook - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Sarepta Therapeutics (SRPT) Q4 2025 earnings summary - Quartr
Price to book forward of Sarepta Therapeutics, Inc. – NASDAQ:SRPT - TradingView
Price to book forward of Sarepta Therapeutics, Inc. – LSE:0L35 - TradingView
Sarepta Therapeutics, Inc. Actuals & Estimates (NASDAQ:SRPT) - TradingView
Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data - Sahm
Enterprise value to EBITDA forward of Sarepta Therapeutics, Inc. – LSE:0L35 - TradingView
FDA Action Update, June 2026: Acceptances, Clearances, and Alignments - NeurologyLive
Sarepta Refused FDA’s Request to Halt Elevidys Shipments - MSN
Enterprise value to EBIT forward of Sarepta Therapeutics, Inc. – LSE:0L35 - TradingView
Enterprise value to revenue forward of Sarepta Therapeutics, Inc. – NASDAQ:SRPT - TradingView
SRPTSarepta Therapeutics Inc Volatility & Greeks - Finviz
ETFs Investing in Sarepta Therapeutics, Inc. Stocks - TradingView
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):